SYNACTHENE RETARD 1 mg/1 ml, suspension for injection i.m. ampoule, 1 ml
Active ingredients: Zinc chloride, TÉTRACOSACTIDE
Commercialized according to BDPMDispensing in France: Prescription only
Suspension for injectionampoule, 1 mlintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- SYNACTHENE RETARD 1 mg/1 ml, suspension injectable I.M.
- Pharmaceutical form
- suspension injectable
- Route of administration
- intramusculaire
- Presentation description
- 1 ampoule(s) en verre de 1 ml
- Marketing authorisation holder
- ALFASIGMA (ITALIE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 31 May 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60034644CIP73102586CIP133400931025863Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORURE DE ZINCsuspension | 1,00 mg · 1 ml de suspension injectable I.M. | SA |
| TÉTRACOSACTIDEsuspension | 1,00 mg · 1 ml de suspension injectable I.M. | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.